Dishman Carbogen Amcis expects CHF 1.5-2 crore Bavla run rate
Key highlights
- Dishman Carbogen Amcis expects a CHF 1.5 crore to CHF 2 crore annual run rate from its first major Bavla transfer.
- Validation batches for the big-pharma transfer are expected by around April.
- Management estimated CHF 2.5 crore to CHF 3 crore of aggregate annual potential across transfers, subject to contracts and prices.
- First-half revenue was Rs 1,185 crore, about 13% below Rs 1,360 crore a year earlier.
powered by IRIS

Dishman Carbogen Amcis Limited expects its first major big-pharma technology transfer to Bavla to generate a CHF 1.5 crore to CHF 2 crore annual revenue run rate once transferred. Management said Bavla laboratory work was progressing smoothly, with validation batches expected by around April under the timeline agreed with the client.
Know Dishman Carbogen Amcis inside out
Results, valuation, peers and who's buying, in one view.
What revenue does Dishman Carbogen Amcis expect from the Bavla transfer?
Dishman Carbogen Amcis expects the transferred molecule to generate a yearly revenue run rate of about CHF 1.5 crore to CHF 2 crore. Harshil Dalal gave that range when asked about the commercial molecule moving to Bavla, while Stephan Fritschi later described it as a significant transfer from a big-pharma customer. The figure is an expected annual run rate after transfer, rather than revenue already reported from the programme.
The stated scale stands against a lower first-half revenue base. Dishman Carbogen Amcis reported Rs 1,185 crore of revenue in the first half, compared with Rs 1,360 crore in the first half of the preceding financial year, a decline of about 13%. Management said it did not expect full-year revenue to grow above the prior year's Rs 2,900 crore, although it expected to get closer to that level by year-end.
Management did not disclose the product name, customer identity, contract duration or the date on which the CHF 1.5 crore to CHF 2 crore run rate could be fully realised. Fritschi identified the customer only as big pharma. The annual range therefore depends on completing the transfer and reaching the related commercial arrangements.
How is Dishman Carbogen Amcis transferring the molecule to Bavla?
Dishman Carbogen Amcis said the transfer follows its normal procedure: technical information has been sent to Bavla, where the team is conducting laboratory development work and adjusting the process to its equipment. Fritschi said the site was becoming familiar with the process and that work had proceeded smoothly so far. Management did not identify a technical issue or surprise affecting the agreed timeline.
The next disclosed milestone is validation batches by around April. Management said the timing had been agreed with the client, but did not specify the date for commercial production, supply or revenue recognition. That means validation-batch completion is the nearest stated operational marker for the major transfer rather than confirmation of commercial sales.
The call did not provide details of a filing change, regulatory approval or a regulatory timetable for the molecule. Instead, management described the sequence as transmission of technical information, laboratory work at Bavla, process adjustment to local equipment and validation batches. Investors have a target of around April for those batches, but no disclosed timetable beyond that step.
Got a follow-up? Ask IRIS
How large is Dishman Carbogen Amcis's wider Bavla transfer pipeline?
Dishman Carbogen Amcis estimated the annual potential across transfers at roughly CHF 2.5 crore to CHF 3 crore, subject to contract and price negotiations. Fritschi initially referred to about CHF 3 crore in aggregate and then described his assumption as CHF 2.5 crore to CHF 3 crore. This wider estimate includes the major big-pharma molecule but is not a committed revenue forecast.
Management said multiple transfers were under way, including about three commercial products, two intermediates, key starting materials and other projects. Key starting materials, or KSMs, are inputs used in pharmaceutical manufacturing. The stated workload shows that the CHF 1.5 crore to CHF 2 crore transfer is part of a broader set of projects involving Carbogen and Bavla.
The wider range has more uncertainty than the single molecule's stated run rate because commercial terms remain open. Fritschi said technical transfers were proceeding in parallel with negotiations over new prices and contracts. Customers expected cost benefits from the Bavla arrangement, according to management, so final revenue will depend on the prices and terms eventually agreed.
Dishman Carbogen Amcis also said it had a handful of outstanding customer quotations involving Carbogen and Bavla. Management did not give those quotations a revenue value, a closing date or a customer count beyond a handful. The CHF 2.5 crore to CHF 3 crore estimate should therefore be treated as management's rough assumption rather than booked order value.
What could affect Dishman Carbogen Amcis's transfer revenue timing?
Dishman Carbogen Amcis said customer requirements can determine when contracted development work is delivered and when milestones are achieved, shifting revenue between quarters. Management cited a development-order pipeline of close to CHF 10 crore with contracts already in place, but said work completed in any quarter depends on customer delivery needs and project milestones.
That mechanism contributed to a softer recent quarter. Dalal said development revenue accruing in August and September was lower than expected because certain orders expected to be completed by the end of September were not completed. Some work was deferred to the next year because of customers' funding situations. Management did not link those deferrals to the Bavla big-pharma transfer.
The transfer programme is being pursued alongside uneven performance at other sites. The French facility recorded about CHF 1 crore of quarterly revenue and negative EBITDA, or earnings before interest, tax, depreciation and amortisation, of roughly CHF 1.73 crore. Management did not connect that French result to Bavla, but said the group was applying cost-control measures and assessing plant, equipment, people and resource use against its expected 12-to-18-month pipeline.
Management also said it was targeting direct Phase III customers to become a second supplier after commercialisation. Manufacturing could be in India or Switzerland, depending on volumes and customer requirements. That business-development approach could create future work across the network, but the call did not state that the Bavla transfer was a Phase III second-supplier project.
Conclusion
Dishman Carbogen Amcis has identified a CHF 1.5 crore to CHF 2 crore annual run rate for its first major big-pharma transfer to Bavla, within a wider rough potential of CHF 2.5 crore to CHF 3 crore. The project has greater definition than the broader pipeline, but neither range represents reported sales, and the wider estimate remains subject to pricing and contract negotiations.
The next disclosed event is validation batches by around April. Thereafter, the pace at which the opportunity becomes revenue will depend on commercial production timing and final contract terms, while management's comments on customer-led development milestones indicate that delivery and revenue can move between reporting quarters.


